Research programme: photodynamic therapeutics - Genisphere/University of Pennsylvania

Drug Profile

Research programme: photodynamic therapeutics - Genisphere/University of Pennsylvania

Alternative Names: Photodynamic 3DNA® therapeutics

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator Genisphere; University of Pennsylvania
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 22 Mar 2016 Preclinical development in Breast cancer in USA (unspecified route)
  • 22 Mar 2016 Genisphere's 3DNA® is available for licensing as of 22 Mar 2016. http://www.genisphere.com/partnering-contact
  • 22 Mar 2016 Genisphere has patent protection for 3DNA drug delivery technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top